Biondvax Pharmaceuticals Ltd

Oct 07, 2019

BiondVax Receives EUR4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial

Jun 26, 2019

European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to EUR24million

Apr 30, 2019

BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update

Nov 26, 2018

BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate

Jun 28, 2018

Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors

Jun 19, 2018

BiondVax Receives Its First EUR6M Tranche Disbursement From the European Investment Bank (EIB)

Dec 27, 2017

BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)

Dec 05, 2017

BiondVax's CEO Issues Letter to Shareholders

Nov 20, 2017

BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine

Sep 18, 2017

BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option

Aug 31, 2017

Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange

Aug 31, 2017

BiondVax Provides Second Quarter 2017 Financial Results and Update